UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (7), p.2548-2553

2014

Volltextzugriff (PDF)

Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing

Blood reviews, 2018-07, Vol.32 (4), p.289-299

2018

Volltextzugriff (PDF)

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

Annals of hematology, 2015-07, Vol.94 (7), p.1127-1138

2015

Volltextzugriff (PDF)

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3641-3649

2015

Volltextzugriff (PDF)

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

Cell reports (Cambridge), 2017-03, Vol.18 (13), p.3204-3218

2017

Volltextzugriff (PDF)

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

Oncotarget, 2016-11, Vol.7 (44), p.72044-72056

2016

Volltextzugriff (PDF)

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Volltextzugriff (PDF)

Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?

Haematologica (Roma), 2017-08, Vol.102 (8), p.1301-1303

Medeiros, Bruno C

2017

Volltextzugriff (PDF)

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

Blood, 2010-09, Vol.116 (13), p.2224-2228

2010

Volltextzugriff (PDF)

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin

PloS one, 2019-07, Vol.14 (7), p.e0219547-e0219547

2019

Volltextzugriff (PDF)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Frontiers in oncology, 2023-05, Vol.13, p.1150149-1150149

2023

Volltextzugriff (PDF)

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

Haematologica (Roma), 2012-01, Vol.97 (1), p.133-136

2012

Volltextzugriff (PDF)

Interpretation of clinical endpoints in trials of acute myeloid leukemia

Leukemia research, 2018-05, Vol.68, p.32-39

Medeiros, Bruno C.

2018

Volltextzugriff (PDF)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Haematologica (Roma), 2018-01, Vol.103 (1), p.101-106

2018

Volltextzugriff (PDF)

Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia

Haematologica (Roma), 2012-09, Vol.97 (9), p.1401-1404

2012

Volltextzugriff (PDF)

Why do Subjects on Clinical Trials Discontinue Therapy? Do We Really Know?

Leukemia research, 2016-12, Vol.51, p.19-21

2016

Volltextzugriff (PDF)

Is there a standard of care for relapsed AML?

Best practice & research. Clinical haematology, 2018-12, Vol.31 (4), p.384-386

Medeiros, Bruno C.

2018

Volltextzugriff (PDF)

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

Haematologica (Roma), 2014-01, Vol.99 (1), p.54-59

2014

Volltextzugriff (PDF)

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

Haematologica (Roma), 2013-04, Vol.98 (4), p.591-596

2013

Volltextzugriff (PDF)

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

Haematologica (Roma), 2015-03, Vol.100 (3), p.331-335

2015

Volltextzugriff (PDF)

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

Haematologica (Roma), 2018-03, Vol.103 (3), p.e106-e109

2018

Volltextzugriff (PDF)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2684-2692

2018

Volltextzugriff (PDF)

Non-zero-sum game of transfusions: EOL in leukemia

Blood, 2018-08, Vol.132 (7), p.676-678

Medeiros, Bruno C.

2018

Volltextzugriff (PDF)

Novel agents in acute myeloid leukemia

International journal of hematology, 2012-08, Vol.96 (2), p.178-185

2012

Volltextzugriff (PDF)

1 – 25 von 470

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(424)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(262)
Life Sciences & Biomedicine
(225)
Humans
(184)
Male
(99)
Female
(97)
Hematology
(89)
Middle Aged
(67)
Oncology
(64)
Aged
(63)
Adult
(62)
Leukemia, Myeloid, Acute - Drug Therapy
(43)
Acute Myeloid Leukemia
(39)
Leukemia, Myeloid, Acute - Genetics
(37)
Treatment Outcome
(37)
Biological And Medical Sciences
(34)
Leukemia, Myeloid, Acute - Mortality
(33)
Prognosis
(32)
Animals
(31)
Adolescent
(30)
Medical Sciences
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

Interpretation of clinical endpoints in trials of acute myeloid leukemia

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia

Why do Subjects on Clinical Trials Discontinue Therapy? Do We Really Know?

Is there a standard of care for relapsed AML?

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Non-zero-sum game of transfusions: EOL in leukemia

Novel agents in acute myeloid leukemia

Suchergebnisse filtern